Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response

Clinical Cancer Research

Volumn 14, Issue 24, 2008, Pages 8279-8287

  Langer, Rupert ^a,i   Ott, Katja ^e   Specht, Katja ^a   Becker, Karen ^a   Lordick, Florian ^f   Burian, Maria ^b   Herrmann, Ken ^c   Schrattenholz, Andre ^g   Cahill, Michael A ^g,h   Schwaiger, Markus ^c   Hofler, Heinz ^a,d   Wester, Hans Jurgen ^c  

^a Institute of Pathology   (Germany)

^b Department of Surgery ^*  (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d National Research Center for Environment and Health   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g PROTEOSYS AG   (Germany)

^h CHARLES STURT UNIVERSITY   (Australia)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOSKELETON PROTEIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GLUCOSE REGULATED PROTEIN 78; GLUCOSE REGULATED PROTEIN 94; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 60; OXALIPLATIN; PACLITAXEL; CHAPERONE; ENDOPLASMIN; HEAT SHOCK PROTEIN; HSPB1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MOLECULAR CHAPERONE GRP78; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER SURGERY; CELLULAR STRESS RESPONSE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR REGRESSION; ADENOCARCINOMA; CHEMISTRY; ESOPHAGUS TUMOR; GENE EXPRESSION PROFILING; GENETICS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED;

ADENOCARCINOMA; ADULT; AGED; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HEAT-SHOCK PROTEINS; HSP27 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MOLECULAR CHAPERONES; PROTEOMICS;

EID: 58149331113     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0679     Document Type: Article

References (50)

1. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993;104:510-3.
2. Powell J, McConkey CC, Gillison EW, Spychal RT. Continuing rising trend in oesophageal adenocarcinoma. Int J Cancer 2002;102:422-7.
3. Lordick F, Stein HJ, Peschel C, Siewert JR. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 2004;91:540-51.
4. WalshTN, Noonan N, Hollywood D, et al. A comparison of mult modal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-7.
5. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11 -20.
6. Zacherl J, Sendler A, Stein HJ, et al. Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus.World J Surg 2003;27:1067 -74.
7. Langer R, Specht K, Becker K, et al. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res 2005;11: 7462-9.
8. Warnecke-Eberz U, Metzger R, Miyazono F, et al. High specificity of quantitative excision repair cross-complementing 1 messenger Rna expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 2004;10:3794-9.
9. Heeren PA,Kloppenberg FW,Hollema H, et al. Predictive effect of P53 and P21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Res 2004;24:2579-83.
10. Luthra R, Luthra MG, Izzo J, et al. Biomarkers of response to preoperative chemoradiation in esophageal cancers. Semin Oncol 2006;33:S2-5.
11. Cho W. Contribution of oncoproteomics to cancer biomarker discovery. Molecular Cancer 2007;6:25.
12. Issaq HJ,VeenstraTD. The role of electrophoresis in disease biomarker discovery. Electrophoresis 2007; 28:1980-8.
13. Righetti PG, Castagna A, Antonioli P, et al. Proteo- mic approaches for studying chemoresistance in cancer. Expert Rev Proteomics 2005;2:215-28.
14. Schrattenholz A, Groebe K. What does it need to be a biomarker? Relationships between resolution, differential quantification and statistical validation ofprotein surrogate biomarkers. Electrophoresis 2007;28: 1970-9.
15. Neubauer H, Clare SE, Kurek R, et al. Breast cancer proteomics by laser capture microdissection, sample pooling, 54-Cm Ipg Ief, and differential iodine radioisotope detection. Electrophoresis 2006;27:1840-52.
16. Wozny W, Schroer K, Schwall GP, et al. Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: cancer association of Annexin A3. Proteomics 2007;7: 313-22.
17. Wozny W, Schwall GP, Sastri CS, et al. Differential proteotope radioactive quantification of protein abundance ratios. Methods Mol Biol. In press 2008.
18. Lordick F, Ott K, Krause BJ, et al. Pet to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the Municon phase Ii trial. Lancet Oncol 2007;8: 797-805.
19. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006;24:4692-8.
20. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarci- nomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-65.
21. Becker K, Mueller JD, Schulmacher C, et al. Histo- morphologyand grading of regression in gastriccarci- noma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521 -30.
22. Cahill MA, Wozny W, Schwall G, et al. Analysis of relative isotopologue abundances for quantitative profiling of complex protein mixtures labelled with the acrylamide/D3-acrylamide alkylation tag system. Rapid Commun Mass Spectrom 2003;17:1283-90.
23. Groebe K, Krause F, Kunstmann B, et al. Differential proteomic profiling of mitochondria from Podospora anserina, rat and human reveals distinct patterns of age-related oxidative changes. Exp Gerontol 2007; 42:887-98.
24. Vogt JA, Schroer K, Holzer K, et al. Protein abundance quantification in embryonic stem cells using incomplete metabolic labelling with 15n amino acids, matrix-assisted laser desorption/ionisation time-of- flight mass spectrometry, and analysis of relative isotopologue abundances of peptides. Rapid Commun Mass Spectrom 2003;17:1273-82.
25. Shevchenko A, Wilm M,Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996;68:850-8.
26. Pappin DJ, Hojrup P, Bleasby AJ. Rapid identification of proteins by peptide-mass fingerprinting. Curr Biol 1993;3:327-32.
27. Specht K, Richter T, Muller U, et al. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001;158:419-29.
28. Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 2001;26:504-10.
29. Ni M, Lee AS. Er chaperones in mammalian development and human diseases. FEBS Lett 2007;581: 3641 -51.
30. Poznanovic S, Wozny W, Schwall GP, et al. Differential radioactive proteomic analysis of microdissected renal cell carcinoma tissue by 54 cm isoelectricfocus- ing in serial immobilized ph gradient gels. J Proteome Res 2005;4:2117-25.
31. Kollermann J, Schlomm T, Bang H, et al. Expression and prognostic relevance of annexin a3 in prostate cancer. Eur Urol 2008;54:1314-23.
32. Castagna A, Antonioli P, Astner H, et al. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 2004;4:3246-67.
33. Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006;97: 813-20.
34. Mavropoulos JC, Fields TA, Pizzo SV. Chaperones and disease. N Engl J Med 2005;353:2821 -2; author reply 21 -2.
35. Melendez K, Wallen ES, Edwards BS, et al. Heat shock protein 70 and glycoprotein 96 aredifferentially expressed on the surface of malignant and nonmalignant breast cells. Cell Stress Chaperones 2006;11: 334-42.
36. Fernandez PM,Tabbara SO, Jacobs LK, et al. Overexpression of the glucose-regulated stress gene Grp 78 in malignant but not benign human breast lesions. Breast Cancer Res Treat 2000;59:15-26.
37. Tang D, Khaleque MA, Jones EL, et al. Expression of heat shock proteins and heat shock protein messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo. Cell Stress Chaperones 2005;10:46-58.
38. Lee AS. Grp78 Induction in cancer: therapeutic and prognostic implications. Cancer Res 2007;67: 3496-9.
39. Langer R, Feith M, Siewert J, Wester H, Hofler H. Expression and clinical significance of glucose regulated proteins Grp78 (Bip) and Grp94 (Gp96) in human adenocarcinomas of the esophagus. BMC Cancer 2008;8:70.
40. Lee E, Nichols P, Spicer D, et al. Grp78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res 2006;66:7849-53.
41. Pootrakul L, Datar RH, Shi SR, et al. Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin Cancer Res 2006;12:5987-93.
42. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis.Trends Biochem Sci 2006;31:164-72.
43. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005;10: 86-103.
44. Vargas-Roig LM, Gago FE,Tello O, Aznar JC, Ciocca DR. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1998;79:468-75.
45. Langdon SP, Rabiasz GJ, Hirst GL, et al. Expression of the heat shock protein Hsp27 in human ovarian cancer. Clin Cancer Res1995;1:1603-9.
46. Takeno S, Noguchi T, Kikuchi R, et al. Immunohisto- chemical study of leukocyte infiltration and expression of Hsp70 in esophageal squamous cell carcinoma. Oncol Rep 2001;8:585-90.
47. Soldes OS, Kuick RD,Thompson IA II, et al. Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas. Br J Cancer 1999;79:595-603.
48. Doak SH, Jenkins GJ, Parry EM, et al. Differential expression of the Mad2, Bub1 and Hsp27 genes in Barrett s oesophagus-their association with aneuploidy and neoplastic progression. Mutat Res 2004;547: 133-44.
49. Hack CJ. Integrated transcriptome and proteome data: the challenges ahead. Brief Funct Genomic Proteomic 2004;3:212-9.
50. Sinha A, Singh C, Parmar D, Singh MP. Proteomics in clinical interventions: achievements and limitations in biomarker development. Life Sci 2007;80: 1345-54.